



UNITED STATE DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

ATTORNEY DOCKET NO. FIRST NAMED INVENTOR FILING DATE APPLICATION NO. V0139/7028 M NEWELL 03/26/99 09/277,575 **EXAMINER** HM22/1004 TUNG, M HELEN C LOCKHART WOLF GREENFIELD & SACKS PAPER NUMBER **ART UNIT** 600 ATLANTIC AVENUE 1644 BOSTON MA 02210

Please find below and/or attached an Office communication concerning this application or

DATE MAILED:

Commissioner of Patents and Trademarks

10/04/00

proceeding.



Office Action Summary

Application No. 09/277,575

Applicant(s)

Newell

Examiner

Mary B. Tung

Group Art Unit 1644

Responsive to communication(s) filed on	
☐ This action is FINAL .	
☐ Since this application is in condition for allowance except for formal in accordance with the practice under Ex parte Quay\\835 C.D. 11	Il matters, prosecution as to the merits is closed
A shortened statutory period for response to this action is set to expire longer, from the mailing date of this communication. Failure to responsible application to become abandoned. (35 U.S.C. § 133). Extensions of the 37 CFR 1.136(a).	month(s), or thirty days, whichever is
Disposition of Claim	
X Claim(s) 1-14, 18, 29, 39, 44, 49-53, 74, 79, and 140	is/are pending in the applicat
Of the above, claim(s)	is/are withdrawn from an in the
Claim(s)	israte withdrawn from consideration
☐ Claim(s)	Is/are allowed.
☐ Claim(s)	is/are rejected.
☐ Claim(s)	is/are objected to.
Claims <u>1-14, 18, 29, 39, 44, 49-53, 74, 79, and 140</u>	are subject to restriction or election requirement.
Application Papers X See the attached Notice of Drofteners and Date (D. 1997)	-
See the attached Notice of Draftsperson's Patent Drawing Revie	
☐ The drawing(s) filed on is/are objected	to by the Examiner.
☐ The proposed drawing correction, filed on	is ☐ approved ☐disapproved.
The specimentation to objected to by the Examiner.	
we saw or designation is objected to by the Examiner.	
Priority under 35 U.S.C. § 119	
☐ Acknowledgement is made of a claim for foreign priority under 3 ☐ All ☐Some* ■ None of the CERTIFIED copies of the priority.	
☐ All ☐Some* None of the CERTIFIED copies of the price ☐ received.	ority documents have been
□ received in Application No. (Series Code/Serial Number) _	
received in this national stage application from the Interna	tional Puropy (PCT Puls 47.0%)
*Certified copies not received:	uonai Buleau (PCT Rule 17.2(a)).
🖄 Acknowledgement is made of a claim for domestic priority under	35 U.S.C. § 119(e)
Attachment(s)	
☐ Notice of References Cited, PTO-892	
☐ Information Disclosure Statement(s), PTO-1449, Paper No(s).	
☐ Interview Summary, PTO-413	
Notice of Draftsperson's Patent Drawing Review, PTO-948	
☐ Notice of Informal Patent Application, PTO-152	
SEE OFFICE ACTION ON THE FO	LLOWING PAGES

Serial No. 09/277, 575 Art Unit 1644

DETAILED ACTION

Claims 1-142 were originally presented.


Claims 15-17, 19-28, 30-38, 40-43, 45, 46, 48, 51, 54-73, 75-78, 80-139, 141 and 142 were cancelled in the paper filed July 13, 1999, Paper No. 3.

Claims 1-14, 18, 29, 39, 44, 47, 49-53, 74, 79 and 140 are pending.

Election/Restriction

Please Note: In an effort to enhance communication with our customers and reduce processing time, Group 1640 is running a Fax Response Pilot for Written Restriction Requirements. A dedicated Fax machine is in place to receive your responses. The Fax number is 703-308-4315. A Fax cover sheet is attached to this Office Action for your convenience. We encourage your participation in this Pilot Program. If you have any questions or suggestions, please contact Paula Hutzell, Supervisory Patent Examiner at paula.hutzell@uspto.gov or 703-308-4310. Thank you in advance for allowing us to enhance our customer service. Please limit the use of this dedicated Fax number to responses to Written Restrictions.

- 1. Restriction to one of the following inventions is required under 35 U.S.C. § 121:
 - I. Claims 1-13, 39 and 44, are drawn to a method for decreasing mitochondrial potential by the administration of a major histocompatability class II HLA-DR molecule, classified in class 514, subclass 21.
 - II. Claims 14, 47 and 49-52 are drawn to a drawn to a method for increasing mitochondrial potential by the administration of a major histocompatability class II HLA-DP/DQ molecule, classified in class 514, subclass 21.
 - III. Claims 18 and 29, drawn to a method for lysis of a mammalian cell using a major histocompatability class II HLA-DR ligand, classified in class 435, subclass 375.
 - IV. Claims 53 and 140, drawn to a drawn to a method for selectively killing a Fasligand bearing tumor cell using acetate, classified in class 435, subclass 375.
 - V. Claims 74 and 79, drawn to a composition comprising an HLA-DR inducing agent and an HLA-DR ligand, classified in class 530, subclass 350.
- 2. The inventions are distinct, each from the other because of the following reasons:
- 3. Groups I-IV are unique methods. They differ with respect to ingredients, process steps and endpoints to achieve different goals. Therefore, they are patentably distinct each from the other.



- 4. Groups V and I are related as product and processes of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (M.P.E.P. 806.05(h)). In the present case, the product as claimed, the HLA-DR ligand can be used in a method of protein purification using affinity chromatography.
- 5. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter and classifications, and because a non-patent literature and/or sequence search of any or these three distinct inventions would not be co-extensive with a search of the others, an examination and search of two or more inventions in a single application would constitute a serious undue burden on the Examiner, restriction for examination purposes as indicated is proper.
- 6. Should Applicants traverse on the ground that the members of the groups are not patentably distinct, Applicant should submit evidence or identify such evidence now of record showing the members to be obvious variants or clearly admit on the record that this is the case. In either instance, if the Examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103 of the other invention.
- 7. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 C.F.R. 1.143).

Conclusion

- Papers related to this application may be submitted to Group 1640 by facsimile transmission. Papers should be faxed to Group 1640 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). THE CM1 FAX CENTER TELEPHONE NUMBER IS (703) 305-3014 or (703) 308-4242.
- Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Mary Tung whose telephone number is (703)308-9344. The Examiner can normally be reached Tuesday through Friday from 8:30 am to 6:00 pm. A message may be left on the Examiner's voice mail service. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the

Serial No. 09/277, 575 Art Unit 1644

status of this application should be directed to the Group 1640 receptionist whose telephone number is (703) 308-0196.

Mary B Jung October 2, 2000

Mary B. Tung, Ph.D.

Patent Examiner

Group 1640